SCHEMBL2885315

SCHEMBL2885315

CCOC(=O)c1ncc2c(cc(-c3ccc(F)cc3)n2-c2ccc(OC)cc2)c1O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.43
IDO1 P14902 1/20 0.43
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
RAB9A P51151 1/20 0.42
GABRA2 P47869 2/20 0.41
GABRB2 P47870 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
PIK3CA P42336 1/20 0.41
TP53 P04637 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2885905 0.94 CHRNA7 (0.48) CHRNA7SMN1; SMN2NPC1LMNARAB9A
SCHEMBL2884720 0.90 ALDH1A1 (0.46) CHRNA7SMN1; SMN2NPC1LMNARAB9A
SCHEMBL2887235 0.83 EGLN1 (0.51)
SCHEMBL2886724 0.82 ALDH1A1 (0.50) SMN1; SMN2NPC1LMNARAB9AGABRA2
SCHEMBL2881006 0.81 LMNA (0.41) SMN1; SMN2IDO1NPC1LMNARAB9A
SCHEMBL2881446 0.80 NPC1 (0.46) CHRNA7NPC1LMNARAB9AGABRA2
SCHEMBL2886487 0.76 CHRNA7 (0.74) CHRNA7SMN1; SMN2TP53
SCHEMBL2887494 0.75 LMNA (0.45) CHRNA7NPC1LMNARAB9AGABRA2
SCHEMBL2884455 0.73 LMNA (0.45) CHRNA7NPC1LMNARAB9AGABRA2
SCHEMBL2887487 0.73 SMN1; SMN2 (0.45) SMN1; SMN2GABRA2GABRB2GABRA1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124489-B1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2020-07-15 EP disclosed
EP-3124489-A1 THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS Fibrogen, Inc. (US) 2017-02-01 EP disclosed
EP-2016078-B1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN INC (US) 2016-06-15 EP disclosed
US-7696223-B2 [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) FIBROGEN, INC. (US) 2010-04-13 US disclosed
EP-2016078-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2009-01-21 EP disclosed
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. 2008-01-03 US disclosed
WO-2007115315-A2 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS FIBROGEN, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004309-A1 PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 CHRNA7 4787/4885SMN1; SMN2 3919/4885IDO1 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.